TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 63-72

  Holoch, Peter A ^a   Griffith, Thomas S ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Apoptosis; Cancer immunotherapy; TRAIL receptor; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; APOMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GELFOAM; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LEXTUMUMAB; MAPATUMUMAB; PACLITAXEL; PEMETREXED; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APPENDIX CANCER; CANCER GENETICS; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; GENE MUTATION; HUMAN; IMMUNE SYSTEM; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 71749102407     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.066     Document Type: Review

References (162)

1. Adams C., Totpal K., Lawrence D., Marsters S., Pitti R., Yee S., Ross S., Deforge L., Koeppen H., Sagolla M., Compaan D., Lowman H., Hymowitz S., and Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15 (2008) 751-761
2. + T cells. Nat. Immunol. 2 (2001) 1010-1017
3. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., Goodwin R.G., Smith C.A., Ramsdell F., and Lynch D.H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181 (1995) 71-77
4. Algeciras-Schimnich A., Griffith T.S., Lynch D.H., and Paya C.V. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J. Immunol. 162 (1999) 5205-5211
5. Arai T., Akiyama Y., Okabe S., Saito K., Iwai T., and Yuasa Y. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. Cancer Lett. 133 (1998) 197-204
6. Armeanu S., Lauer U.M., Smirnow I., Schenk M., Weiss T.S., Gregor M., and Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 63 (2003) 2369-2372
7. Armitage R.J. Tumor necrosis factor receptor superfamily members and their ligands. Curr. Opin. Immunol. 6 (1994) 407-413
8. Ashkenazi A., Holland P., and Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26 (2008) 3621-3630
9. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
10. Aydin C., Sanlioglu A.D., Karacay B., Ozbilim G., Dertsiz L., Ozbudak O., Akdis C.A., and Sanlioglu S. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum. Gene Ther. 18 (2007) 39-50
11. Barnhart B.C., Alappat E.C., and Peter M.E. The CD95 type I/type II model. Semin. Immunol. 15 (2003) 185-193
12. + T cell help. J. Exp. Med. 186 (1997) 65-70
13. + anaplastic large cell lymphoma. Leukemia 21 (2007) 838-842
14. Bremer E., van Dam G.M., de Bruyn M., van Riezen M., Dijkstra M., Kamps G., Helfrich W., and Haisma H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol. Ther. 16 (2008) 1919-1926
15. Brooks A.D., Ramirez T., Toh U., Onksen J., Elliott P.J., Murphy W.J., and Sayers T.J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. N.Y. Acad. Sci. 1059 (2005) 160-167
16. Buneker C., Mohr A., and Zwacka R.M. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncol. Rep. 21 (2009) 1289-1295
17. Camidge D., Herbst R.S., Gordon M., Eckhardt S., Kurzroc R., Durbin B., Ing J., Ling J., Sager J., and Mendelson D. A phase I safety and pharmacokinetic study of apomab, a human TRAIL-R2 agonist antibody, in patients with advanced cancer [abstract]. J. Clin. Oncol. 25 (2007) 3582
18. + cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum. Gene Ther. 17 (2006) 1225-1240
19. Cassatella M.A., Huber V., Calzetti F., Margotto D., Tamassia N., Peri G., Mantovani A., Rivoltini L., and Tecchio C. Interferon-activated neutrophils store a TNF-related apoptosis- inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J. Leukoc. Biol. 79 (2006) 123-132
20. Cerami A., and Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 9 (1988) 28-31
21. Cha S.S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C., Sung Y.C., and Oh B.H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11 (1999) 253-261
22. Chemistry C.o.P.a. Absorbable gelatin sponge-new and nonofficial remedies. JAMA 135 (1947) 921
23. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., and Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1754-1759
24. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., and Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18 (2000) 509-514
25. Chow L.Q., Eckhardt S.G., Gustafson D.L., O'Bryant C., Hariharan S., Diab S., Fox N.L., Corey A., Padavic K., Brown M., and Cohen R.B. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase 1 and PK study [abstract]. J. Clin. Oncol. 24 (2006) 2515
26. Clohessy J.G., Zhuang J., de Boer J., Gil-Gomez G., and Brady H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281 (2006) 5750-5759
27. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
28. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
29. Degli-Esposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.-P., DuBose R.F., Goodwin R.G., and Smith C.A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186 (1997) 1165-1170
30. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
31. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., Morici L.A., Lenz L.L., Cado D., Riley L.W., and Winoto A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21 (2004) 877-889
32. Dong F., Wang L., Davis J.J., Hu W., Zhang L., Guo W., Teraishi F., Ji L., and Fang B. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin. Cancer Res. 12 (2006) 5224-5230
33. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
34. Dyer M.J., MacFarlane M., and Cohen G.M. Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol. 25 (2007) 4505-4506
35. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
36. Fanger N.A., Maliszewski C.R., Schooley K., and Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190 (1999) 1155-1164
37. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 8 (2008) 132-140
38. Fulda S., and Debatin K.M. HDAC inhibitors: double edge sword for TRAIL cancer therapy?. Cancer Biol. Ther. 4 (2005) 1113-1115
39. Fulda S., and Debatin K.M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur. J. Cancer 41 (2005) 786-798
40. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 (2002) 2283-2294
41. Fulda S., Wick W., Weller M., and Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8 (2002) 808-815
42. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13 (1999) 1817-1824
43. Geserick P., Drewniok C., Hupe M., Haas T.L., Diessenbacher P., Sprick M.R., Schon M.P., Henkler F., Gollnick H., Walczak H., and Leverkus M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 27 (2008) 3211-3220
44. Gliniak B., and Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 59 (1999) 6153-6158
45. Goodman L.S., and Gliman A. Surface-acting drugs. The Pharmacologic Basis of Therapeutics, ed. 6 (1980), MacMillan Publishing Co, New York 955
46. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., and Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
47. Griffith T.S., Anderson R.D., Davidson B.L., Williams R.D., and Ratliff T.L. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol. 165 (2000) 2886-2894
48. Griffith T.S., and Broghammer E.L. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol. Ther. 4 (2001) 257-266
49. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., and Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
50. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161 (1998) 2833-2840
51. Griffith T.S., Fialkov J.M., Scott D.L., Azuhata T., Williams R.D., Wall N.R., Altieri D.C., and Sandler A.D. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 62 (2002) 3093-3099
52. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., and Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189 (1999) 1343-1354
53. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., and Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 (1996) 1363-1366
54. Herbst R.S., Mendolson D.S., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., Ing J., Kurzrock R., Novotny W., and Eckhardt G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer [abstract]. J. Clin. Oncol. 24 (2006) 3013
55. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., and Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19 (2000) 5477-5486
56. Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M., Kelley R.F., Ashkenazi A., and de Vos A.M. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4 (1999) 563-571
57. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., and Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
58. Itoh N., and Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem. 268 (1993) 10932-10937
59. Janssen E.M., Droin N.M., Lemmens E.E., Pinkoski M.J., Bensinger S.J., Ehst B.D., Griffith T.S., Green D.R., and Schoenberger S.P. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88-93
60. Jeng Y.M., and Hsu H.C. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett. 181 (2002) 205-208
61. Jin Z., Dicker D.T., and El-Deiry W.S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1 (2002) 82-89
62. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 (2000) 564-567
63. Johnson T.R., Stone K., Nikrad M., Yeh T., Zong W.X., Thompson C.B., Nesterov A., and Kraft A.S. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22 (2003) 4953-4963
64. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
65. Kagawa S., He C., Gu J., Koch P., Rha S.J., Roth J.A., Curley S.A., Stephens L.C., and Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61 (2001) 3330-3338
66. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 (1999) 1451-1460
67. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., and Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59 (1999) 734-741
68. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
69. Kemp T.J., Ludwig A.T., Earel J.K., Moore J.M., Vanoosten R.L., Moses B., Leidal K., Nauseef W.M., and Griffith T.S. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2 L. Blood 106 (2005) 3474-3482
70. Kemp T.J., Moore J.M., and Griffith T.S. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J. Immunol. 173 (2004) 892-899
71. Kim Y.H., Lee D.H., Jeong J.H., Guo Z.S., and Lee Y.J. Quercetin augments TRAIL- induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem. Pharmacol. 75 (2008) 1946-1958
72. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
73. Kock N., Kasmieh R., Weissleder R., and Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 9 (2007) 435-442
74. Koga Y., Matsuzaki A., Suminoe A., Hattori H., and Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 64 (2004) 1037-1043
75. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
76. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., and Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
77. Lee J., Hampl M., Albert P., and Fine H.A. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 4 (2002) 312-323
78. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y., Lee J.H., Han S.Y., Park J.Y., Oh R.R., Jang J.J., Han J.Y., Lee J.Y., and Yoo N.J. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59 (1999) 5683-5686
79. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y., Lee J.H., Han S.Y., Park J.Y., Oh R.R., Kang C.S., Kim K.M., Jang J.J., Nam S.W., Lee J.Y., and Yoo N.J. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 20 (2001) 399-403
80. Lee T.J., Lee J.T., Park J.W., and Kwon T.K. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351 (2006) 1024-1030
81. Lee Y.C., Simamora P., and Yalkowsky S.H. Systemic delivery of insulin via an enhancer-free ocular device. J. Pharm. Sci. 86 (1997) 1361-1364
82. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
83. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., and Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (2004) 1471-1474
84. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
85. Lillehammer T., Engesaeter B.O., Prasmickaite L., Maelandsmo G.M., Fodstad O., and Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J. Gene Med. 9 (2007) 440-451
86. Liu X., Yue P., Khuri F.R., and Sun S.Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64 (2004) 5078-5083
87. Ludwig A.T., Moore J.M., Luo Y., Chen X., Saltsgaver N.A., O'Donnell M.A., and Griffith T.S. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 64 (2004) 3386-3390
88. Luster T.A., Carrell J.A., McCormick K., Sun D., and Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther. 8 (2009) 292-302
89. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., and Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272 (1997) 25417-25420
90. Machan L., Burt H.M., and Hunter W.L. Local delivery of chemotherapy: a supplement to existing cancer treatments. A case for surgical pastes and coated stents. Adv. Drug Deliv. Rev. 26 (1997) 199-207
91. Marini P., Schmid A., Jendrossek V., Faltin H., Daniel P.T., Budach W., and Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5 (2005) 5
92. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., and Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
93. Mizutani Y., Yoshida O., Miki T., and Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin. Cancer Res. 5 (1999) 2605-2612
94. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., and Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23 (2004) 6261-6271
95. Ndozangue-Touriguine O., Sebbagh M., Merino D., Micheau O., Bertoglio J., and Breard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27 (2008) 6012-6022
96. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276 (2001) 10767-10774
97. Ng C.P., and Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 1 (2002) 1051-1058
98. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., and Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61 (2001) 759-763
99. Oldenhuis C., Mom C., Sleijfer S., Gietema J.A., Fox N.L., Corey A., Eskens F., Loos W., de Vries E.G., and Verweij J. A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin [abstract]. J. Clin. Oncol. 26 (2008) 3540
100. Pai S.I., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D., and El-Deiry W.S. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 58 (1998) 3513-3518
101. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
102. Pan G., Ni J., Yu G., Wei Y.F., and Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424 (1998) 41-45
103. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
104. Park M.S., and Kim Y.B. Sustained release of antibiotic from a fibrin-gelatin-antibiotic mixture. Laryngoscope 107 (1997) 1378-1381
105. Park W.S., Lee J.H., Shin M.S., Park J.Y., Kim H.S., Kim Y.S., Park C.H., Lee S.K., Lee S.H., Lee S.N., Kim H., Yoo N.J., and Lee J.Y. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121 (2001) 1219-1225
106. Petrucci E., Pasquini L., Petronelli A., Saulle E., Mariani G., Riccioni R., Biffoni M., Ferretti G., Benedetti-Panici P., Cognetti F., Scambia G., Humphreys R., Peschle C., and Testa U. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol. Oncol. 105 (2007) 481-492
107. Pineau P., Nagai H., Prigent S., Wei Y., Gyapay G., Weissenbach J., Tiollais P., Buendia M.A., and Dejean A. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene 18 (1999) 3127-3134
108. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
109. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., Barrett M., Judson I., Kaye S., Fox N.L., Halpern W., Corey A., Calvert H., and de Bono J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6194
110. Pollack I.F., Erff M., and Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 7 (2001) 1362-1369
111. Ray S., Bucur O., and Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10 (2005) 1411-1418
112. Rosato R.R., Almenara J.A., Coe S., and Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67 (2007) 9490-9500
113. Sanlioglu A.D., Dirice E., Aydin C., Erin N., Koksoy S., and Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5 (2005) 54
114. Sanlioglu A.D., Karacay B., Koksal I.T., Griffith T.S., and Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther. 14 (2007) 976-984
115. Sayers T.J., Brooks A.D., Koh C.Y., Ma W., Seki N., Raziuddin A., Blazar B.R., Zhang X., Elliott P.J., and Murphy W.J. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102 (2003) 303-310
116. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott F.L., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh J.M., Houghten R.A., and Reed J.C. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
117. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
118. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., and Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 254 (1998) 439-459
119. Sedger L.M., Glaccum M.B., Schuh J.C., Kanaly S.T., Williamson E., Kayagaki N., Yun T., Smolak P., Le T., Goodwin, R., and Gliniak B. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32 (2002) 2246-2254
120. Seol J.Y., Park K.H., Hwang C.I., Park W.Y., Yoo C.G., Kim Y.W., Han S.K., Shim Y.S., and Lee C.T. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 10 (2003) 540-548
121. Shankar S., Singh T.R., and Srivastava R.K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61 (2004) 35-49
122. Sheikh M.S., Huang Y., Fernandez-Salas E.A., El-Deiry W.S., Friess H., Amundson S., Yin J., Meltzer S.J., Holbrook N.J., and Fornace Jr. A.J. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18 (1999) 4153-4159
123. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
124. Shiiki K., Yoshikawa H., Kinoshita H., Takeda M., Ueno A., Nakajima Y., and Tasaka K. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ. 7 (2000) 939-946
125. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., Lee J.H., Lee S.K., Lee S.N., Jung S.S., Han J.Y., Kim H., Lee J.Y., and Yoo N.J. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61 (2001) 4942-4946
126. Siegmund D., Hadwiger P., Pfizenmaier K., Vornlocher H.P., and Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol. Med. 8 (2002) 725-732
127. Siemens D.R., Austin J.C., Hedican S.P., Tartaglia J., and Ratliff T.L. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. J. Natl. Cancer Inst. 92 (2000) 403-412
128. Siemens D.R., Iwasawa T., Austin J.C., Williams R.D., See W.A., Hedican S.P., Tartaglia J., Flynn C.M., Cohen M.B., Rodgers J., and Ratliff T.L. Biomarker distribution after injection into the canine prostate: implications for gene therapy. BJU Int. 86 (2000) 1076-1083
129. Sikic B., Wakelee H., von Mehren M., Lewis N., Plummer E.R., Calvert A.H., Fox N.L., Kumm E., Jones S., and Burris H. abstract. AACR Meeting Abstracts (2007) B72
130. Simons M.P., Leidal K.G., Nauseef W.M., and Griffith T.S. TNF-related apoptosis- inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J. Leukoc. Biol. 83 (2008) 621-629
131. Simons M.P., Moore J.M., Kemp T.J., and Griffith T.S. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect. Immun. 75 (2007) 1265-1271
132. Sinicrope F.A., Penington R.C., and Tang X.M. Tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 10 (2004) 8284-8292
133. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76 (1994) 959-962
134. Spierings D.C., de Vries E.G., Vellenga E., van den Heuvel F.A., Koornstra J.J., Wesseling J., Hollema H., and de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 52 (2004) 821-831
135. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., and Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
136. Stepnick D.W., Peterson M.K., Bodgan C., Davis J., Wasman J., and Mailer K. Effects of tumor necrosis factor alpha and vascular permeability factor on neovascularization of the rabbit ear flap. Arch. Otolaryngol. Head Neck Surg. 121 (1995) 667-672
137. Stieglmaier J., Bremer E., Kellner C., Liebig T.M., ten Cate B., Peipp M., Schulze-Koops H., Pfeiffer M., Buhring H.J., Greil J., Oduncu F., Emmerich B., Fey G.H., and Helfrich W. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother. 57 (2008) 233-246
138. Takimoto R., and El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19 (2000) 1735-1743
139. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
140. Tecchio C., Huber V., Scapini P., Calzetti F., Margotto D., Todeschini G., Pilla L., Martinelli G., Pizzolo G., Rivoltini L., and Cassatella M.A. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103 (2004) 3837-3844
141. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., Hill M., Mays T., McCoy T., Fox N.L., Halpern W., Corey A., and Cohen R.B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25 (2007) 1390-1395
142. Vaculova A., Hofmanova J., Soucek K., and Kozubik A. Different modulation of TRAIL- induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL- resistant colon cancer cells. FEBS Lett. 580 (2006) 6565-6569
143. + T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 67 (2007) 11980-11990
144. VanOosten R.L., Moore J.M., Karacay B., and Griffith T.S. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2 L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol. Ther. 4 (2005) 1104-1112
145. VanOosten R.L., Moore J.M., Ludwig A.T., and Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 11 (2005) 542-552
146. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., and Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
147. Voelkel-Johnson C., King D.L., and Norris J.S. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 9 (2002) 164-172
148. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Bhanot U., Hasel C., Moller P., Gschwend J.E., Simmet T., Debatin K.M., and Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 69 (2009) 2425-2434
149. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 (2007) 1070-1077
150. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A., Goodwin R.G., and Rauch C.T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (1997) 5386-5397
151. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
152. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
153. Wenger T., Mattern J., Haas T.L., Sprick M.R., Walczak H., Debatin K.M., Buchler M.W., and Herr I. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. 14 (2007) 316-326
154. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
155. Williams S.A., and McConkey D.J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 63 (2003) 7338-7344
156. Yang F., Shi P., Xi X., Yi S., Li H., Sun Q., and Sun M. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med. Oncol. 23 (2006) 191-204
157. Yee L., Fanale M., Dimick K., Calvert S., Robins C., Ing J., Ling J., Novotny W., Ashkenazi A., and Burris I.H. (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma [abstract]. J. Clin. Oncol. 25 (2007) 8078
158. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., and Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 88 (1998) 2375-2380
159. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., and Hersey P. Relation of TNF- related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59 (1999) 2747-2753
160. Zhang Y., Ma H., Zhang J., Liu S., Liu Y., and Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 82 (2008) 1154-1161
161. Zheng L., Fisher G., Miller R.E., Peschon J., Lynch D.H., and Lenardo M.J. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377 (1995) 348-351
162. Zhu H., Guo W., Zhang L., Davis J.J., Wu S., Teraishi F., Cao X., Smythe W.R., and Fang B. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol. Ther. 4 (2005) 393-397